CLINICAL_TRIALS
trial_result
· 2017-01-05
Clinical Trial Update: Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma [Phase 2]
Summary
A phase 2 trial of Gleevec (imatinib) in relapsed/refractory T-cell non-Hodgkin lymphoma has completed enrollment and posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dana-Farber Cancer Institute | Conditions: T Cell Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-01-05